RecruitingNot applicableNCT06246630
In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor
Studying Neuroendocrine neoplasm of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ruijin Hospital
- Principal Investigator
- Jiabin JIN, PhDRuijin Hospital
- Intervention
- Chemotherapy and targeted-therapy guided by organoid drug sensitivity test(other)
- Enrollment
- 20 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality, China
Collaborators
Chongqing Kingbiotech Co.,Ltd
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06246630 on ClinicalTrials.govOther trials for Neuroendocrine neoplasm of pancreas
Additional recruiting or active studies for the same condition.